ACMD Events
Advances in Cell and Gene Therapies Symposium 2026
Join experts from healthcare, industry and academia to explore whether we’re ready for in vivo, and discuss local capabilities, emerging technologies, and the current state of the sector.
Join discussions on the development and clinical application of therapies, including patient, industry and investor perspectives.
Sessions:
- State of the sector
- Local sector capabilities
- Regulatory platforms rather than regulated products
- Panel session – Are we ready for in vivo?
- Emerging technologies
- Patient voice
- Networking
Speakers:
- Keynote (Online): Professor Fyodor Urnov (UC Berkeley)
- Chris Alma (Platypus Bio)
- Mike Bettess (Brandon Capital)
- Dr Keefe Chan (Cartherics)
- Dr Samantha Chan (RMH, WEHI)
- Dr Christina Cortez-Jugo (Uni Melb)
- Associate Professor Andrew Deans (SVI)
- Bettina Dietmair (UQ)
- Dr Astrid Glaser (SVI)
- Professor Simon Harrison (PMCC, RMH)
- Dr Miles Horton (RMH, WEHI)
- Professor Misty Jenkins AO (WEHI)
- Michael Krieg (ACMD)
- Associate Professor Max Lim (SVI)
- Lisa Lombardi (Cerulea Clinical Trials)
- Vasily Medvedev (Viral Vector Manufacturing Facility)
- Professor Jane Oliaro (PMCC)
- Dr Jacqui Schiesser (MCRI)
- Professor John Skerritt AM (Uni Melb)
- Dr Thomas Wechsler (ex J&J Gene Therapy)
Who should attend?
Those looking to transition preclinical research proof of concept studies to product development, clinicians designing or implementing clinical trials for cell and gene therapies, and those interested in understanding the sector landscape.
Organised on behalf of the MACH Cell and Gene Therapies Committee.
Kindly sponsored by The Aikenhead Centre for Medical Discovery, St Vincent’s Institute for Medical Research, Decode Science, and Scientifix.
